[go: up one dir, main page]

WO2001047549A3 - Conjugate useful as building block for vaccine preparation - Google Patents

Conjugate useful as building block for vaccine preparation Download PDF

Info

Publication number
WO2001047549A3
WO2001047549A3 PCT/GB2000/004951 GB0004951W WO0147549A3 WO 2001047549 A3 WO2001047549 A3 WO 2001047549A3 GB 0004951 W GB0004951 W GB 0004951W WO 0147549 A3 WO0147549 A3 WO 0147549A3
Authority
WO
WIPO (PCT)
Prior art keywords
building block
vaccine preparation
conjugate useful
conjugate
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/004951
Other languages
French (fr)
Other versions
WO2001047549A2 (en
Inventor
Jane Nicola Zuckerman
Bala Subramaniyam Ramesh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Publication of WO2001047549A2 publication Critical patent/WO2001047549A2/en
Publication of WO2001047549A3 publication Critical patent/WO2001047549A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018Lipids, e.g. in lipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A polymerisable compound for use as a medicament, comprising a peptide; a spacer covalently linked to the peptide; and a monomer unit covalently linked to the spacer and capable of forming a polymer with at least one further monomer unit in a further polymerisable compound.
PCT/GB2000/004951 1999-12-23 2000-12-21 Conjugate useful as building block for vaccine preparation Ceased WO2001047549A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9930585A GB9930585D0 (en) 1999-12-23 1999-12-23 Component for vaccine
GB9930585.6 1999-12-23

Publications (2)

Publication Number Publication Date
WO2001047549A2 WO2001047549A2 (en) 2001-07-05
WO2001047549A3 true WO2001047549A3 (en) 2001-12-27

Family

ID=10866996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004951 Ceased WO2001047549A2 (en) 1999-12-23 2000-12-21 Conjugate useful as building block for vaccine preparation

Country Status (2)

Country Link
GB (1) GB9930585D0 (en)
WO (1) WO2001047549A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275178B (en) * 2013-05-21 2015-04-29 首都医科大学 Preparation of n-dodecanoic acid-RGD (arginine-glycine-aspartic acid)-n-tetradecanol mediated fanny targeted liposome, and evaluation of anti-tumor activity
EP3773483A4 (en) * 2018-04-06 2022-01-26 Amma Therapeutics, Inc. CONTROLLED RELEASE THERAPEUTIC COMPOSITION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034968A1 (en) * 1997-02-11 1998-08-13 The Council Of The Queensland Institute Of Medical Research Polymers incorporating peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034968A1 (en) * 1997-02-11 1998-08-13 The Council Of The Queensland Institute Of Medical Research Polymers incorporating peptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 101, no. 21, 19 November 1984, Columbus, Ohio, US; abstract no. 189405, PETROV, R. V. ET AL: "Vaccinating effect of conjugates of influenza virus surface antigens with synthetic polymer carrier" XP002167382 *
D C JACKSON ET AL.: "Free radical induced polymerization of synthetic peptides into polymeric immunogens", VACCINE., vol. 15, no. 15, 1997, BUTTERWORTH SCIENTIFIC. GUILDFORD., GB, pages 1697 - 1705, XP002167381, ISSN: 0264-410X *
DOKL. AKAD. NAUK SSSR (1984), 277(3), 752-5 [IMMUNOL.], 1984 *
N M O'BRIEN-SIMPSON ET AL.: "Polymerization of unprotected synthetic peptides: a view toward synthetic peptide vaccines", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 119, no. 6, 1997, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., US, pages 1183 - 1188, XP002167380, ISSN: 0002-7863 *

Also Published As

Publication number Publication date
WO2001047549A2 (en) 2001-07-05
GB9930585D0 (en) 2000-02-16

Similar Documents

Publication Publication Date Title
AU3177700A (en) Polymers, their preparation and uses
PT1572728E (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2000041538A3 (en) Dermal compositions
AU2001241423A1 (en) Needleless syringe
CA2332559A1 (en) High molecular weight medicine-containing preparation in powder form for administration through mucosa
AU2002225762A1 (en) Preparation of polymerization catalysts
AU3958100A (en) New compounds, their preparation and use
AU3958200A (en) New compounds, their preparation and use
WO2003000226A3 (en) Pharmaceutical compositions containing polymer and drug assemblies
AU2002233986A1 (en) Rigid soluble materials for use with needle-less infusion sets, sensor sets and injection devices and methods of making the same
AU2003289641A1 (en) The novel coumarin-amide derivatives and its preparation, said drug composition and its use
WO2003086369A3 (en) Stealthy polymeric biodegradable nanospheres and uses thereof
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU6303800A (en) Improvements in or relating to polymers
AU2002213181A1 (en) Nanostructures formed through cyclohexadiene polymerization
AU2922600A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
AU2001235773A1 (en) Electro-luminiscent polymers, their preparation and uses
AU2001277605A1 (en) High molecular weight cationic polymers, preparation method and uses thereof
WO2004029073A3 (en) Conjugates comprised of polymer and hiv gp41-derived peptides and their use in therapy
WO2001047549A3 (en) Conjugate useful as building block for vaccine preparation
AU2001260110A1 (en) Novel LHRH-antagonists, Production and Use Thereof as Medicament
ZA200110244B (en) Novel xanthone compounds, their preparation and use as medicament.
AUPR218000A0 (en) Polymer gels and their preparation
AU2001268653A1 (en) Combination hiv therapy including camptothecin
AU6846500A (en) Novel 8-carbonyl chroman derivatives, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP